Using AGN1 LOEP to treat osteoporosis in women
Official title: Prospective, Post-market Evaluation of Safety and Efficacy of a Local Osteo- Enhancement Procedure (LOEP) in the Proximal Femur of Women in Europe with Osteoporosis
Run by AgNovos Healthcare, LLC · NCT05202678 · Data updated 2026-11-12
This study is testing a new procedure called AGN1 LOEP to see if it can help postmenopausal women with osteoporosis build new bone in their hips.
Quick facts
| Study type | Interventional |
|---|---|
| Sex | Women only |
| Enrollment | 150 (estimated) |
| Sponsor | AgNovos Healthcare, LLC Industry-sponsored |
| Drugs / interventions | radiation |
| Locations | 1 site (Sint-Niklaas, Antwerpen) |
| Status | Recruiting |
| Started | July 5, 2021 |
| Main results expected | December 2025 |
| Study ends | December 2026 |
| Registry record updated | January 31, 2025 |
| Trial ID | NCT05202678 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are postmenopausal women with osteoporosis and a femoral neck DXA T-score of -2.5 or less who have at least one intact hip.
✕Probably not a fit
Patients who have had recent hip surgeries or fractures, or those with severe intra-articular arthritis may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This research involves a prospective, post-market, multi-center evaluation of AGN1 LOEP, a procedure aimed at forming new bone in the proximal femur of postmenopausal women with osteoporosis. The study will enroll up to 150 participants across 20 sites in Europe and will be non-randomized and open-label. Participants will undergo follow-up evaluations at multiple time points to assess safety, clinical performance, and patient satisfaction. Key assessments will include bone density scans and various health evaluations over a two-year period.
Why it matters
Potential benefit: If successful, this procedure could significantly improve bone density and reduce the risk of hip fractures in women with osteoporosis.
How similar studies have gone: While this approach is innovative, it is based on existing techniques for enhancing bone density, and similar studies have shown promise in improving outcomes for osteoporosis patients.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Subject is a postmenopausal female (at least 1-year post menses). 2. Subject has bone loss in the hip attributable to osteoporosis as defined by a femoral neck DXA T-score of -2.5 or less. 3. Subject has at least one hip without previous surgery or fracture. 4. Subject is medically stable from any previous treatment or medical procedure in the opinion of the investigator and with an ASA score of I or II. 5. Subject has willingness, ability, and commitment to participate in baseline and follow-up evaluations for the full length of the study. 6. Subject is capable of giving written informed consent to participate in the study. Exclusion Criteria: 1. Subject is less than 3 months removed from having a hip fracture repair or prosthesis or elective Total Hip Arthroplasty (THA). 2. Subject has progressive increase in hip pain over the previous six (6) months that in the opinion of the Investigator suggests moderate to severe intra-articular arthritis, labral tear, extraarticular soft tissue pathology, referred pain, tumor, stress fracture or infection. 3. Subject is dependent on the use of a wheelchair or is bedridden. 4. Subject has albumin corrected serum calcium levels outside the normal lab range or has a pre-existing calcium metabolism disorder (e.g., hypercalcemia). 5. Subject has severe renal insufficiency defined as an estimated glomerular filtration rate (eGFR) \< 30 mL/min or is being treated with dialysis. 6. Subject has hemoglobin A1c level ≥ 7.5%. 7. Subject has Body Mass Index (BMI) \> 35. 8. Subject exhibits excessive smokeless tobacco use or excessive smoking as determined by the principal investigator\*. 9. Subject is at ASA Class III, IV, V or VI. 10. Subject exhibits excessive alcohol consumption as determined by the principal investigator\*. 11. Subject has radiological evidence of gross bony or joint pathology of the hip, including signs predictive of atypical femoral fractures (e.g., Cortical beaking) or has been diagnosed and/or treated for atypical femoral fractures. 12. Subject treated with corticosteroids or systemic glucocorticoids for ten (10) days in the previous six (6) months. 13. Subject has history of oral or parenteral use of immunesuppressive drugs in the previous twelve months. 14. Subject has history of metabolic bone disease other than osteoporosis (ex. Paget's disease). 15. Subject has a history of auto-immune arthritic diseases including rheumatoid, psoriatic, or those associated with systemic lupus erythematosus, spondyloarthropathy, Reiter's Syndrome or Crohn's Disease. 16. Subject has a history of radiation therapy to the hip or pelvic region. 17. Subject has a history of any invasive malignancy (except basal cell carcinoma), unless treated and with no clinical signs or symptoms of the malignancy for five (5) years. 18. Subject has known allergies to implanted device. 19. In the judgement of the Investigator, the subject is not a good study candidate (e.g., inability to maintain follow-up schedule, comorbidity or poor general physical/mental health, or drug or alcohol abuse issues). 20. Subject is currently enrolled in another clinical study. \*AgNovos's recommendation is \>1 pack per day smoking and \>3 alcoholic drinks per day
Where it's running
-
AZ Nikolaas
Sint-Niklaas, Antwerpen, Belgium Recruiting
Study contacts
- Principal investigator: Jo De Schepper, MD — AZ Nikolaas
- Study coordinator: Adam Lowe
- Email: info@agnovos.com
- Phone: +1 240 753 6500
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Role of LH and hCG in adults being evaluated for endocrine disorders
This study looks at whether levels of luteinizing hormone (LH) and hCG in adults undergoing endocrine evaluation relate to their disease presence and outcomes.
-
Can a blood marker called lumican reveal hidden fragility in postmenopausal osteoporosis
This study tests whether serum lumican levels can help identify hidden fragility risk in postmenopausal women beyond what bone density shows.
-
Functional Muscle-Bone Incongruity Index: A look at muscle strength and bone health in adults
This observational study tests a composite FKUI score using handgrip strength and hip/spine bone density to see if it better reflects musculoskeletal health than each measure alone in adults undergoing routine DXA.
-
Vessel-X Bone Filling Container System for Vertebral Augmentation
A new minimally invasive vertebral augmentation approach tests the Vessel-X device to see if it safely improves pain and function in people with osteoporotic vertebral compression fractures.
-
Proximal Humerus Cortical Thickness in Post-Stroke Paresis
This study tests whether measurements of the outer bone thickness of the upper arm (the humerus) on the paretic side after a stroke reflect regional bone loss and how well they agree with standard bone density tests.
-
People with Osteoporosis: See if Walk-BEST Gait Program Helps You Walk Safer
This pilot study tests whether older adults with osteoporosis can use the Walk-BEST gait training with a wearable sensor to walk more safely and reduce fall risk.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.